For Quick Alerts
For Daily Alerts

Glenmark Pharma To Study Potential COVID-19 Drug Combo; Shares Gain 5th Straight Day


Shares of Glenmark Pharma rose as much as 2.4 percent to Rs 360.5 apiece for the fifth straight day on Tuesday after the drugmaker informed the exchanges that it will be commencing a new phase of 3 clinical trials on hospitalised patients of moderate COVID-19 cases in India using a combination of two anti-viral drugs- Favipiravir and Umifenovir.

It has been the longest winning streak for the stock in over a month.

Glenmark Pharma To Study Potential COVID-19 Drug Combo; Shares Gain

The company has received permission from the regulator for the same and will look at enrolling 158 patients of the moderate COVID-19 for trial and randomised into 2 groups. It will be a new randomised, open-label study.

"The two antiviral drugs have different mechanism of action, and their combination may demonstrate improved treatment efficacy by effectively tackling high viral loads in patients during early stage of disease," the company said in a statement.

"This is another step in our effort is to launch a treatment for COVID-19 patients and we are looking at every possibility. We will do all it takes to ensure accessibility of the product across the country if the clinical trials are successful," Sujesh Vasudevan, President, India Formulations, Middle East and Africa business, Glenmark Pharmaceuticals Ltd.

Last month, Glenmark said it would conduct clinical trials in India of just favipiravir as a potential treatment for COVID-19.

Read more about: glenmark pharma
Company Search
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more